Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 52,329Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 9Revlimid

02 3Revlimid

03 1Revlimid - BMS

04 1Revlimid - Celgene

PharmaCompass

01

Brand Name : Revlimid

Lenalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Revlimid

arrow
2024 ACI Convention
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 12,106

2019 Revenue in Millions : 9,378

Growth (%) : 29

blank

02

Brand Name : Revlimid

Lenalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Revlimid

arrow
2024 ACI Convention
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 77

2020 Revenue in Millions : 52

Growth (%) : 48

blank

03

Brand Name : Revlimid

Lenalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Revlimid

arrow
2024 ACI Convention
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 12,821

2020 Revenue in Millions : 12,106

Growth (%) : 6

blank

04

Brand Name : Revlimid

Lenalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Revlimid

arrow
2024 ACI Convention
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 83

2021 Revenue in Millions : 77

Growth (%) : 8

blank

05

Brand Name : Revlimid

Lenalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Revlimid

arrow
2024 ACI Convention
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 9,978

2021 Revenue in Millions : 12,821

Growth (%) : -22

blank

06

Brand Name : Revlimid

Lenalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Revlimid

arrow
2024 ACI Convention
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 6,097

2022 Revenue in Millions : 9,978

Growth (%) : -39

blank

07

Brand Name : Revlimid

Lenalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Revlimid

arrow
2024 ACI Convention
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 82

2022 Revenue in Millions : 83

Growth (%) : -4

blank

08

Brand Name : Revlimid

Lenalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Revlimid

arrow
2024 ACI Convention
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Blood Related Disorders

Currency : USD

2015 Revenue in Millions : 4,980

2014 Revenue in Millions : 5,801

Growth (%) : 16%

blank

09

Brand Name : Revlimid

Lenalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Revlimid

arrow
2024 ACI Convention
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 8,187

2016 Revenue in Millions : 6,974

Growth (%) : 17

blank

10

Brand Name : Revlimid

Lenalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Revlimid

arrow
2024 ACI Convention
Not Confirmed

Lenalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 6,974

2015 Revenue in Millions : 5,801

Growth (%) : 20

blank